Predictors of Fast Response to Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir ± Ribavirin in Real Life Amber Study in Genotype 1 and 4 HCV Infected Patients as a Rationale for Shortening of Treatment

Authors :: Jolanta Białkowska
M. Lucejko
Maciej Jabłkowski
Marta Wawrzynowicz-Syczewska
Magdalena Tudrujek
Iwona Mozer-Lisewska
Waldemar Halota
Ewa Karpińska
A. Grabinska
Ewa Janczewska
Krzysztof Tomasiewicz
Alicja Wiercińska-Drapało
Dorota Zarębska-Michaluk
Khalil Nazzal
K. Rostkowska
Anna Piekarska
Brygida Knysz
Katarzyna Fleischer-Stępniewska
Robert Flisiak
Hanna Berak
Wiesław Kryczka
Jerzy Jaroszewicz
Beata Bolewska
Arkadiusz Pisula
Aleksander Garlicki
Olga Tronina
Kornelia Karwowska
Andrzej Horban
Source :: ResearcherID, Web of Science
Publication Year :: 2016
Publisher :: Elsevier BV, 2016.

Subjects :: Hepatology
business.industry
Ribavirin
Virology
Ombitasvir/Paritaprevir/ Ritonavir/Dasabuvir
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
chemistry
Genotype
In real life
Medicine
030211 gastroenterology & hepatology
030212 general & internal medicine
business

Full Text Access

Tools